Article

Elastomeric pumps for ambulatory patient controlled regional analgesia

Department of Anesthesia, London Health Sciences Centre, University of Western Ontario, Canada.
Canadian Journal of Anaesthesia (Impact Factor: 2.5). 10/2000; 47(9):897-902. DOI: 10.1007/BF03019672
Source: PubMed

ABSTRACT To report our experience with the use of the (Eclipse) elastomeric pump for ambulatory Patient Controlled Regional Analgesia (PCRA) METHOD: After a pilot study using this device in patients admitted to the hospital, seven patients received PCRA at home using the elastomeric pump. Patients with a variety of continuous regional anesthetic blocks were sent home with written and verbal instructions regarding the use of this device, boluses, side effects of local anesthetics and removal of block catheters. Patients were contacted daily to collect data with regards to the efficacy of the block, problems associated with the use of this device and their satisfaction with the method of analgesia.
During the pilot study there were two catheter disconnections requiring rescue analgesics. Two patients had the entire contents of the bulb delivered over several minutes. Among the seven patients receiving PCRA at home, one patient had to be admitted to the hospital. One patient had block catheter slip out during transit. The volume delivered could not be measured. Patients found it difficult to know if the drug had been delivered. Three patients noted that the pumps were empty earlier than expected. One patient found it difficult to change the bulb. No patient had difficulty with catheter removal or with bolusing.
PCRA offers excellent postoperative analgesia at home. Elastomeric pumps facilitate PCRA but are imprecise with drug delivery and may not be safe for epidural infusions. The safety of this device for peripheral nerve blocks should be evaluated further.

Download full-text

Full-text

Available from: Sugantha Ganapathy, Mar 31, 2015
1 Follower
 · 
339 Views
  • Anesthesia & Analgesia 02/1998; 86(1):86-9. DOI:10.1097/00000539-199801000-00017 · 3.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ropivacaine, a new local anesthetic now under Federal Drug Administration review for clinical release, is a unique drug designed to take advantage of cardiac sodium channel stereoselectivity. The Labat lecture, honoring the father of regional anesthesia, pays tribute to the master by tracing the evolution of knowledge transfer from basic science frontiers to safer clinical practice. A survey was made of pertinent English-language literature on stereoselectivity of bupivacaine isomers and the evaluation and validation of ropivacaine, including a stereoisomerism primer for the nonscientist. A synopsis of current basic and (pre)clinical findings, preparing North American clinicians for the imminent introduction of ropivacaine, is presented, along with predictions for potential clinical application. Bupivacaine cardiotoxicity results from prolonged sodium channel dwell time of the R(ectus), as compared with the S(inister), stereoisomer. Bupivacaine, like most aminoamide local anesthetics (except lidocaine), has a chiral (asymmetric) carbon atom where the amide linkage joins the hydrophilic tail. Chirality yields two steric forms (S and R) which are spatial mirror images (like the left hand trapped in a right glove) with different receptor kinetics; commercial bupivacaine is the optically inactive racemic (RS) mixture of R- and S-bupivacaine. Ropivacaine is unique in that membrane separation synthesis exclusively yields the S-monomer, which is a local anesthetic with lower cardiotoxic potential than racemic bupivacaine. Its immediate clinical application would be in obstetric analgesia, whereas its shorter duration of action and weaker motor block should make it useful in ambulatory anesthesia.
    Regional anesthesia 01/1995; 20(6):474-81.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of a disposable, elastomeric infusion device was evaluated in 55 patients receiving home antimicrobial therapy. During a 30-day period, all patients referred to five service centers to receive home antimicrobial therapy for at least one week were enrolled in the study. Pharmacists used an automated pump to fill 110-mL, 100-mL/hr elastomeric devices (Homepump; Block Medical, Carlsbad, CA). Nurses trained patients to use the device. Nurses and pharmacists completed an evaluation form for each patient. Fifty-five patients received a total of 1938 doses; a fresh device was used to administer each dose. Nurses described patient teaching for the device as easy (51) or no different from that for other devices (4). Patient acceptance was reported to be good in 54 patients and poor in 1 patient. A total of 91 restarts were required; 36 patients needed more than one restart. The failure rate of the device was 1.6%; 25 of 44 reported problems occurred in devices that were frozen and thawed before use. The Homepump was determined to be an acceptable device for the intermittent infusion of small-volume antimicrobial solutions in the home environment because of its low failure rate and high degree of patient and nursing preference; its drawbacks include high cost and slowed infusion rates for units that are not thawed properly after freezing.
    American journal of hospital pharmacy 08/1992; 49(7):1712-6.